JP7059372B2 - デュアルモードの放射性トレーサーおよび療法剤 - Google Patents

デュアルモードの放射性トレーサーおよび療法剤 Download PDF

Info

Publication number
JP7059372B2
JP7059372B2 JP2020526688A JP2020526688A JP7059372B2 JP 7059372 B2 JP7059372 B2 JP 7059372B2 JP 2020526688 A JP2020526688 A JP 2020526688A JP 2020526688 A JP2020526688 A JP 2020526688A JP 7059372 B2 JP7059372 B2 JP 7059372B2
Authority
JP
Japan
Prior art keywords
oligo
bond
acid
bonds
amide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020526688A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020528461A5 (enExample
JP2020528461A (ja
Inventor
ワーザー，アレクサンデル・ヨーゼフ
ウェスター，ハンス－ユルゲン
アイバー，マティアス・ヨハネス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Technische Universitaet Muenchen
Original Assignee
Technische Universitaet Muenchen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technische Universitaet Muenchen filed Critical Technische Universitaet Muenchen
Publication of JP2020528461A publication Critical patent/JP2020528461A/ja
Publication of JP2020528461A5 publication Critical patent/JP2020528461A5/ja
Priority to JP2022065524A priority Critical patent/JP2022101601A/ja
Application granted granted Critical
Publication of JP7059372B2 publication Critical patent/JP7059372B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Nuclear Medicine (AREA)
JP2020526688A 2017-07-28 2018-07-30 デュアルモードの放射性トレーサーおよび療法剤 Active JP7059372B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022065524A JP2022101601A (ja) 2017-07-28 2022-04-12 デュアルモードの放射性トレーサーおよび療法剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17183795.8 2017-07-28
EP17183795 2017-07-28
PCT/EP2018/070533 WO2019020831A1 (en) 2017-07-28 2018-07-30 AGENTS WITH TWO RADIOTRATIVE AND THERAPEUTIC MODES

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022065524A Division JP2022101601A (ja) 2017-07-28 2022-04-12 デュアルモードの放射性トレーサーおよび療法剤

Publications (3)

Publication Number Publication Date
JP2020528461A JP2020528461A (ja) 2020-09-24
JP2020528461A5 JP2020528461A5 (enExample) 2021-04-01
JP7059372B2 true JP7059372B2 (ja) 2022-04-25

Family

ID=59501286

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020526688A Active JP7059372B2 (ja) 2017-07-28 2018-07-30 デュアルモードの放射性トレーサーおよび療法剤
JP2022065524A Pending JP2022101601A (ja) 2017-07-28 2022-04-12 デュアルモードの放射性トレーサーおよび療法剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022065524A Pending JP2022101601A (ja) 2017-07-28 2022-04-12 デュアルモードの放射性トレーサーおよび療法剤

Country Status (20)

Country Link
US (3) US11413360B2 (enExample)
EP (3) EP3658194B1 (enExample)
JP (2) JP7059372B2 (enExample)
KR (2) KR102752620B1 (enExample)
CN (1) CN111132700B (enExample)
AU (2) AU2018308699B2 (enExample)
BR (1) BR112020001785A2 (enExample)
CA (1) CA3071315A1 (enExample)
DK (1) DK3658194T3 (enExample)
EA (1) EA202090370A1 (enExample)
ES (1) ES3011272T3 (enExample)
FI (1) FI3658194T3 (enExample)
HU (1) HUE070098T2 (enExample)
IL (2) IL318092A (enExample)
MX (2) MX2020000352A (enExample)
PL (1) PL3658194T3 (enExample)
PT (1) PT3658194T (enExample)
SG (1) SG11202000725WA (enExample)
WO (1) WO2019020831A1 (enExample)
ZA (1) ZA202000467B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11413360B2 (en) * 2017-07-28 2022-08-16 Technische Universität München Dual mode radiotracer and—therapeutics
AU2020213678B2 (en) 2019-01-30 2024-05-30 Technische Universität München PSMA binding dual mode radiotracer and therapeutic
WO2020157128A1 (en) * 2019-01-30 2020-08-06 Technische Universität München Silicon-fluoride acceptor substituted radiopharmaceuticals and precursors thereof
IL303420A (en) * 2019-01-30 2023-08-01 Univ Muenchen Tech Diagnostic imaging materials for cancer
CN112168978B (zh) * 2019-07-03 2022-01-11 北京大学 一种抗体偶联药物及其药物组合物与应用
CA3155519A1 (en) * 2019-10-29 2021-05-06 Steve Shih-Lin Huang Psma-targeting imaging agents
CN113350531A (zh) * 2020-03-02 2021-09-07 上海核力星医药科技有限公司 前列腺特异性膜抗原结合配体偶联物及其应用
GB202005282D0 (en) * 2020-04-09 2020-05-27 Blue Earth Diagnostics Ltd Pharmaceutical Formulations
EP4185336A1 (en) 2020-07-23 2023-05-31 Technische Universität München Silicon-containing ligand compounds
WO2022051684A1 (en) 2020-09-03 2022-03-10 Curium Us Llc Radiolabeling and formulation for scale up of 64cu-dotatate
EP4023250A1 (en) 2021-01-04 2022-07-06 Technische Universität München Dual mode radiotracer and -therapeutics
JP2024507343A (ja) * 2021-02-15 2024-02-19 テクニシェ ユニバーシタット ミュンヘン デュアルモード放射性トレーサーおよびその療法
IL308414A (en) * 2021-05-14 2024-01-01 Technische Universit?T M?Nchen Radiopharmaceutical somatostatin receptor ligands and their precursors
GB202108779D0 (en) 2021-06-18 2021-08-04 Blue Earth Diagnostics Ltd Si-at therapeutic/diagnostic compounds
GB202109922D0 (en) 2021-07-09 2021-08-25 Blue Earth Diagnostics Ltd Radiotracers and therapeutics binding to fibroblast activation protein (fap)
WO2023012282A1 (en) * 2021-08-05 2023-02-09 Technische Universität München Ligand compounds comprising a chelating group as a bridging group
GB202113646D0 (en) 2021-09-24 2021-11-10 Blue Earth Diagnostics Ltd Method of preparation of 18F labelled silyl-fluoride compounds
CN114671806B (zh) * 2022-04-08 2024-03-01 上海如絮生物科技有限公司 一种亲水性吡啶衍生物、中间体、其制备方法及应用
GB202207372D0 (en) 2022-05-19 2022-07-06 Blue Earth Diagnostics Ltd Synthesis of fluorosilyl compounds
CA3257852A1 (en) 2022-07-29 2024-02-01 Technische Universitat Munchen Silicon Fluoride Accepting Groups for Radiopharmaceutical Products
WO2024054226A1 (en) * 2022-09-06 2024-03-14 Hoang Ba Xuan Gallium nitrate and dimethyl sulfoxide composition for respiratory treatment
JP2025532619A (ja) * 2022-09-20 2025-10-01 テクニシェ ユニバーシタット ミュンヘン イメージングおよび標的化放射線治療のための新規ミニガストリン由来コレシストキニン２受容体結合分子
TW202426433A (zh) 2022-09-23 2024-07-01 瑞士商紐利迪姆股份公司 成纖維細胞活化蛋白（ｆａｐ）抑制劑、ｆａｐ結合物及其診斷與治療用途
JP2025539087A (ja) * 2022-11-14 2025-12-03 アクティス オンコロジー， インコーポレイテッド 腎臓におけるミニタンパク質の減少された保持
WO2025072791A2 (en) 2023-09-29 2025-04-03 Aktis Oncology, Inc. Miniproteins, conjugates & uses thereof
GB202316239D0 (en) 2023-10-24 2023-12-06 Blue Earth Diagnostics Ltd Therapeutic combination

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995001346A1 (en) * 1993-06-30 1995-01-12 Akzo Nobel N.V. Chelating compounds
CA2455598A1 (en) 2001-07-27 2003-02-13 Targesome, Inc. Lipid constructs as therapeutic and imaging agents
CN102626522B (zh) * 2012-04-12 2014-09-10 韩彦江 基于趋化因子受体cxcr4多肽类拮抗剂的多肽放射性诊断与治疗药物
AU2015273934B2 (en) * 2014-06-10 2020-08-20 3B Pharmaceuticals Gmbh Conjugate comprising a neurotensin receptor ligand and use thereof
WO2016062370A1 (en) 2014-10-20 2016-04-28 Deutsches Krebsforschungszentrum 18f-tagged inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
US20160287730A1 (en) * 2015-03-31 2016-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Labeled evans blue dye derivative for in vivo serum albumin labeling
US10800797B2 (en) * 2015-05-26 2020-10-13 California Institute Of Technology Heteroaromatic silicon-fluoride-acceptors useful for 18F labeling of molecules and biomolecules, and methods of preparing same
US11413360B2 (en) 2017-07-28 2022-08-16 Technische Universität München Dual mode radiotracer and—therapeutics
WO2019115547A1 (en) * 2017-12-11 2019-06-20 Technische Universität München Psma ligands for imaging and endoradiotherapy
IL303420A (en) 2019-01-30 2023-08-01 Univ Muenchen Tech Diagnostic imaging materials for cancer
AU2020213678B2 (en) 2019-01-30 2024-05-30 Technische Universität München PSMA binding dual mode radiotracer and therapeutic

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Angew Chem Int Ed Engl，2011年，vol.50, no.39，p.9167-9170
Bioconjugate Chemistry，2014年，vol.25，p.738-749
Bioconjugate Chemistry，2015年，vol.26，p.2350-2359

Also Published As

Publication number Publication date
US12453787B2 (en) 2025-10-28
ES3011272T3 (en) 2025-04-07
FI3658194T3 (fi) 2025-02-28
WO2019020831A1 (en) 2019-01-31
MX2020000352A (es) 2020-08-17
AU2018308699A1 (en) 2020-01-23
AU2018308699B2 (en) 2023-11-30
IL272291B2 (en) 2025-06-01
IL272291B1 (en) 2025-02-01
JP2022101601A (ja) 2022-07-06
CN111132700B (zh) 2022-12-13
KR20240027896A (ko) 2024-03-04
DK3658194T3 (da) 2025-02-17
BR112020001785A2 (pt) 2020-09-29
HUE070098T2 (hu) 2025-05-28
PL3658194T3 (pl) 2025-09-15
AU2024200440A1 (en) 2024-02-08
EP3658194A1 (en) 2020-06-03
EP4424378A3 (en) 2024-12-11
US20220370649A1 (en) 2022-11-24
SG11202000725WA (en) 2020-02-27
KR20200064057A (ko) 2020-06-05
ZA202000467B (en) 2022-06-29
PT3658194T (pt) 2025-02-13
US20250121102A1 (en) 2025-04-17
US12390540B2 (en) 2025-08-19
JP2020528461A (ja) 2020-09-24
EA202090370A1 (ru) 2020-05-25
KR102752620B1 (ko) 2025-01-10
IL272291A (en) 2020-03-31
MX2023007914A (es) 2023-07-13
CN111132700A (zh) 2020-05-08
IL318092A (en) 2025-02-01
AU2024200440B2 (en) 2025-04-24
US20200197545A1 (en) 2020-06-25
US11413360B2 (en) 2022-08-16
EP3658194B1 (en) 2024-11-27
CA3071315A1 (en) 2019-01-31
EP4000640A1 (en) 2022-05-25
EP4424378A2 (en) 2024-09-04

Similar Documents

Publication Publication Date Title
JP7059372B2 (ja) デュアルモードの放射性トレーサーおよび療法剤
JP7393485B2 (ja) 前立腺特異的膜抗原（ｐｓｍａ）の標識インヒビター、前立腺癌の治療のための画像化剤および薬剤としてのその使用
JP7549585B2 (ja) がん診断用画像化剤
CN113677400B (zh) 结合psma的双模式放射性示踪剂及治疗剂
KR20230160806A (ko) 이중 모드 방사성 트레이서 및 치료법
US20230277698A1 (en) Silicon-containing ligand compounds
HK40022705A (en) Dual mode radiotracer and -therapeutics
HK40022705B (en) Dual mode radiotracer and -therapeutics
EA046402B1 (ru) Двухрежимная радиоактивная метка и радиотерапевтическое средство

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210218

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210218

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220324

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220413

R150 Certificate of patent or registration of utility model

Ref document number: 7059372

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250